Oxytocin Effect on Attention Inhibition

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

71 participants

Study Classification

INTERVENTIONAL

Study Start Date

2017-12-19

Study Completion Date

2018-08-28

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Effects of intranasal oxytocin (24IU) on cognitive control of attention

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Oxytocin's Effect on Attention Training

NCT03128242

Healthy

UNKNOWN NA

Oxytocin's Effects on Face Attentional Processing

NCT04413786

Healthy

COMPLETED NA

Oxytocin and Dopamine's Effect on Vicarious Optimism

NCT03891095

Oxytocin Group L-DOPA Group Placebo Group

COMPLETED NA

The Effects of Vasopressin on Attention Control

NCT04493554

Healthy

COMPLETED NA

The Effects of Oral Vasopressin on Attention Control: An Eye-tracking Study

NCT06329037

Healthy

RECRUITING NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The cognitive control of attention towards neutral and emotional stimuli represents a key functional domain and disruptions in this domain have been associated with a range of psychiatric disorders. Saccadic eye movement tasks have been used to assess individual differences in the cognitive control of attention and alterations in psychiatric disorders. Recent evidence suggests that the hypothalamic neuropeptide Oxytocin (OXT) may modulate attention allocation and regulation. To this end the present randomized between-subject placebo-controlled experiment examined whether intranasal OXT modulates behavior in an eye-tracking saccade / anti-saccade paradigm in healthy male subjects. The paradigm used non-social (neutral shape) as well as social (happy, sad, angry, fear, and neutral faces) stimuli to explore emotion-specific effects of OXT.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Healthy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

oxytocin group

Group Type EXPERIMENTAL

oxytocin treatment

Intervention Type DRUG

intranasal administration of oxytocin (24IU)

placebo group

Group Type PLACEBO_COMPARATOR

placebo treatment

Intervention Type DRUG

intranasal administration of placebo

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

oxytocin treatment

intranasal administration of oxytocin (24IU)

Intervention Type DRUG

placebo treatment

intranasal administration of placebo

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Male, healthy participants
* Non smokers

Exclusion Criteria

* Previous or current medical, psychiatric, neurological disorder
* Regular medication
* Use of any psychoactive substances in the 24 hours before experiment
* Contra-indications for oxytocin
* Contra-indications for eye-tracking data acquisition

Minimum Eligible Age

18 Years

Maximum Eligible Age

30 Years

Eligible Sex

MALE

Accepts Healthy Volunteers

Yes